208 related articles for article (PubMed ID: 29171017)
1. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract][Full Text] [Related]
2. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
Ahmadi SE; Rahimi S; Zarandi B; Chegeni R; Safa M
J Hematol Oncol; 2021 Aug; 14(1):121. PubMed ID: 34372899
[TBL] [Abstract][Full Text] [Related]
3. MYC-mediated synthetic lethality for treatment of hematological malignancies.
Li X; Zhang XA; Xie W; Li X; Huang S
Curr Cancer Drug Targets; 2015; 15(1):53-70. PubMed ID: 25564254
[TBL] [Abstract][Full Text] [Related]
4. MYC in oncogenesis and as a target for cancer therapies.
Albihn A; Johnsen JI; Henriksson MA
Adv Cancer Res; 2010; 107():163-224. PubMed ID: 20399964
[TBL] [Abstract][Full Text] [Related]
5. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
6. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
7. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications.
Sewastianik T; Prochorec-Sobieszek M; Chapuy B; Juszczyński P
Biochim Biophys Acta; 2014 Dec; 1846(2):457-67. PubMed ID: 25199984
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc.
Lin TC; Lin PL; Cheng YW; Wu TC; Chou MC; Chen CY; Lee H
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1532-9. PubMed ID: 25990966
[TBL] [Abstract][Full Text] [Related]
9. Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.
Adams CM; Hiebert SW; Eischen CM
Cancer Res; 2016 Feb; 76(3):736-48. PubMed ID: 26676759
[TBL] [Abstract][Full Text] [Related]
10. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.
de Jonge AV; Roosma TJ; Houtenbos I; Vasmel WL; van de Hem K; de Boer JP; van Maanen T; Lindauer-van der Werf G; Beeker A; Timmers GJ; Schaar CG; Soesan M; Poddighe PJ; de Jong D; Chamuleau ME
Eur J Cancer; 2016 Mar; 55():140-6. PubMed ID: 26820684
[TBL] [Abstract][Full Text] [Related]
12. Family matters: How MYC family oncogenes impact small cell lung cancer.
Brägelmann J; Böhm S; Guthrie MR; Mollaoglu G; Oliver TG; Sos ML
Cell Cycle; 2017 Aug; 16(16):1489-1498. PubMed ID: 28737478
[TBL] [Abstract][Full Text] [Related]
13. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.
Zhou Z; Patel M; Ng N; Hsieh MH; Orth AP; Walker JR; Batalov S; Harris JL; Liu J
BMC Cancer; 2014 Dec; 14():944. PubMed ID: 25495526
[TBL] [Abstract][Full Text] [Related]
14. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
15. Small molecules remain on target for c-Myc.
Sun L; Gao P
Elife; 2017 Jan; 6():. PubMed ID: 28100396
[TBL] [Abstract][Full Text] [Related]
16. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
Wang W; Hu S; Lu X; Young KH; Medeiros LJ
Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma.
Devlin JR; Hannan KM; Hein N; Cullinane C; Kusnadi E; Ng PY; George AJ; Shortt J; Bywater MJ; Poortinga G; Sanij E; Kang J; Drygin D; O'Brien S; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
Cancer Discov; 2016 Jan; 6(1):59-70. PubMed ID: 26490423
[TBL] [Abstract][Full Text] [Related]
18. MYC, MYCL, and MYCN as therapeutic targets in lung cancer.
Massó-Vallés D; Beaulieu ME; Soucek L
Expert Opin Ther Targets; 2020 Feb; 24(2):101-114. PubMed ID: 32003251
[No Abstract] [Full Text] [Related]
19. Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.
Thng DKH; Toh TB; Chow EK
Trends Pharmacol Sci; 2021 Mar; 42(3):166-182. PubMed ID: 33422376
[TBL] [Abstract][Full Text] [Related]
20. Utility of immunohistochemistry with an antibody against MYC at the initial diagnosis of follicular lymphoma, grade 3A, for predicting a more aggressive clinical course: a case report and review of the literature.
Ichikawa K; Aritaka N; Ogura K; Hosone M; Ota Y; Sato E; Komatsu N; Hirano T
Int J Clin Exp Pathol; 2015; 8(6):7559-64. PubMed ID: 26261669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
